Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis
LP Salm, B Van der Hiel… - Nuclear medicine …, 2012 - journals.lww.com
Neurolymphomatosis (NL) is a rare clinical entity that is defined as infiltration of the nervous
system by a known or unknown haematological malignancy and is difficult to diagnose …
system by a known or unknown haematological malignancy and is difficult to diagnose …
[HTML][HTML] 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
…, HJM Groen, W Uyterlinde, B van der Hiel… - Annals of …, 2022 - Elsevier
Background Programmed cell death protein 1 (PD-1) antibody treatment is standard of care
for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients …
for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients …
[HTML][HTML] Optimal left ventricular lead position assessed with phase analysis on gated myocardial perfusion SPECT
…, P Dibbets-Schneider, B van der Hiel… - European journal of …, 2011 - Springer
Purpose The aim of the current study was to evaluate the relationship between the site of
latest mechanical activation as assessed with gated myocardial perfusion SPECT (GMPS) …
latest mechanical activation as assessed with gated myocardial perfusion SPECT (GMPS) …
High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)
…, DMS Berger, WMC Klop, B van der Hiel… - … journal of cancer, 2019 - Wiley Online Library
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1),
which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable …
which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable …
Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
…, S Balduzzi, CL Zuur, WMC Klop, B van der Hiel… - Critical Reviews in …, 2022 - Elsevier
Abstract Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of
unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement …
unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement …
The role of 18F‐FDG PET/CT in retroperitoneal sarcomas—A multicenter retrospective study
…, S Hendry, FL Vissers, B Van der Hiel… - Journal of surgical …, 2021 - Wiley Online Library
Background The role of 18F‐fluorodeoxyglucose positron emission tomography/computed
tomography (18F‐FDG PET/CT) in the evaluation of retroperitoneal sarcomas is poorly …
tomography (18F‐FDG PET/CT) in the evaluation of retroperitoneal sarcomas is poorly …
[HTML][HTML] Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection …
…, MW Rohaan, WMC Klop, B van der Hiel… - Annals of …, 2021 - journals.lww.com
Objective: To evaluate the potency of short-term neoadjuvant cytoreductive therapy with
dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in …
dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in …
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model
Abstract Background Talimogene laherparepvec (T-VEC) is a genetically modified herpes
simplex type 1 virus and known as an effective oncolytic immunotherapy for injectable …
simplex type 1 virus and known as an effective oncolytic immunotherapy for injectable …
Detection of early onset of hypophysitis by 18F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab
B Van der Hiel, CU Blank, JBAG Haanen… - Clinical nuclear …, 2013 - journals.lww.com
Ipilimumab is a human monoclonal antibody directed against a receptor expressed on
activated T-lymphocytes (CTLA-4). Binding to this receptor induces T-cell activation against …
activated T-lymphocytes (CTLA-4). Binding to this receptor induces T-cell activation against …
Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology: Part IIIa: Therapy response monitoring in breast cancer, lymphoma and gliomas
B Van der Hiel, EKJ Pauwels, MPM Stokkel - Journal of cancer research …, 2001 - Springer
Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (FDG) is considered to
be a very useful adjunct to anatomic imaging techniques and is now primarily used for …
be a very useful adjunct to anatomic imaging techniques and is now primarily used for …